• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy.

作者信息

Zametkin A, Rapoport J L, Murphy D L, Linnoila M, Ismond D

出版信息

Arch Gen Psychiatry. 1985 Oct;42(10):962-6. doi: 10.1001/archpsyc.1985.01790330042005.

DOI:10.1001/archpsyc.1985.01790330042005
PMID:3899047
Abstract

Fourteen boys (mean age, 9.2 +/- 1.5 years) with Attention Deficit Disorder (ADD) With Hyperactivity were treated with dextroamphetamine sulfate or a monoamine oxidase inhibitor (MAOI) (six received clorgyline, eight received tranylcypromine sulfate) for four weeks each in a double-blind, cross-over study that included a two-week placebo washout between active drug periods. The MAOIs had immediate, clinically significant benefit and were clinically indistinguishable from dextroamphetamine. Most children responded to both stimulant and MAOI. These findings of equivalent efficacy of MAOIs in ADD are in contrast to our previous studies with neurotransmitter system selective agents, which showed only weak effects, and suggest that multiple neurotransmitter alterations may be required for stimulant drug effects in ADD. The immediate response to MAOIs indicates a different mechanism from that mediating antidepressant effect. The MAOIs may be useful alternate treatments in selected cases of ADD.

摘要

相似文献

1
Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy.
Arch Gen Psychiatry. 1985 Oct;42(10):962-6. doi: 10.1001/archpsyc.1985.01790330042005.
2
Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment.用单胺氧化酶抑制剂治疗多动儿童。II. 治疗后的血浆和尿液单胺研究结果。
Arch Gen Psychiatry. 1985 Oct;42(10):969-73. doi: 10.1001/archpsyc.1985.01790330049006.
3
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication.兴奋剂与单胺氧化酶抑制剂联合使用:用途综述及一种可能的额外适应症
J Clin Psychiatry. 2004 Nov;65(11):1520-4. doi: 10.4088/jcp.v65n1113.
4
New drug trials in attention deficit disorder.注意力缺陷障碍的新药试验。
Psychopharmacol Bull. 1985;21(2):232-6.
5
Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.单胺氧化酶抑制剂治疗难治性重度抑郁症。对三环类抗抑郁药治疗无效的患者中溴法罗明与反苯环丙胺的双盲比较。
J Affect Disord. 1993 Jul;28(3):189-97. doi: 10.1016/0165-0327(93)90104-r.
6
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.单胺氧化酶抑制剂、三环类抗抑郁药及直接兴奋剂联合治疗难治性抑郁症。
J Clin Psychiatry. 1985 Jun;46(6):206-9.
7
Bupropion treatment of attention-deficit hyperactivity disorder in adults.安非他酮治疗成人注意力缺陷多动障碍
Am J Psychiatry. 1990 Aug;147(8):1018-20. doi: 10.1176/ajp.147.8.1018.
8
Platelet MAO and measures of attention and impulsivity in boys with attention deficit disorder and hyperactivity.
Psychiatry Res. 1986 Jun;18(2):179-88. doi: 10.1016/0165-1781(86)90029-6.
9
Drug treatment for hyperactive children. Therapeutic guidelines.多动症儿童的药物治疗。治疗指南。
Drugs. 1993 Nov;46(5):863-71. doi: 10.2165/00003495-199346050-00006.
10
A naturalistic assessment of the motor activity of hyperactive boys. II. Stimulant drug effects.对多动男孩运动活动的自然主义评估。II. 兴奋剂药物的作用。
Arch Gen Psychiatry. 1983 Jun;40(6):688-93. doi: 10.1001/archpsyc.1983.04390010098013.

引用本文的文献

1
Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis.药物治疗儿童和青少年注意缺陷多动障碍的疗效和安全性:网络荟萃分析。
Eur Child Adolesc Psychiatry. 2018 Oct;27(10):1335-1345. doi: 10.1007/s00787-018-1125-0. Epub 2018 Feb 19.
2
Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.全基因组关联数据分析突显了精神医学药物再定位的候选者。
Nat Neurosci. 2017 Oct;20(10):1342-1349. doi: 10.1038/nn.4618. Epub 2017 Aug 14.
3
Prevalence and assessment of biochemical parameters of attention-deficit hyperactivity disorder children in Bangladesh.
孟加拉国注意缺陷多动障碍儿童生化参数的患病率及评估
J Basic Clin Pharm. 2016 Jun;7(3):70-4. doi: 10.4103/0976-0105.183261.
4
Monoamine oxidase inhibitors: clinical review.单胺氧化酶抑制剂:临床综述。
Can Fam Physician. 1990 Jun;36:1151-5.
5
Candidate gene studies of ADHD: a meta-analytic review.注意力缺陷多动障碍的候选基因研究:一项荟萃分析综述
Hum Genet. 2009 Jul;126(1):51-90. doi: 10.1007/s00439-009-0694-x. Epub 2009 Jun 9.
6
Non-stimulant medications in the treatment of ADHD.非兴奋剂药物治疗注意力缺陷多动障碍
Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I102-16. doi: 10.1007/s00787-004-1010-x.
7
Drug therapy for adults with attention-deficit hyperactivity disorder.针对成人注意力缺陷多动障碍的药物治疗
Drugs. 2003;63(22):2395-411. doi: 10.2165/00003495-200363220-00002.
8
Dopamine genes and attention-deficit hyperactivity disorder: a review.多巴胺基因与注意力缺陷多动障碍:综述
J Psychiatry Neurosci. 2003 Jan;28(1):27-38.
9
Assessing the molecular genetics of attention networks.评估注意力网络的分子遗传学。
BMC Neurosci. 2002 Oct 4;3:14. doi: 10.1186/1471-2202-3-14.
10
Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder.当前治疗注意力缺陷多动障碍的药物治疗建议。
Drugs. 1998 Aug;56(2):215-23. doi: 10.2165/00003495-199856020-00005.